Genetic medicine at the RNA level: Modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing

Robert G. Pergolizzi, Ronald Crystal

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Gene therapy is conventionally carried out by transferring genetic material to the target cell where the exogenous gene is expressed using the endogenous transcription and translation machinery in parallel with the target cell genome. This review focuses on a new paradigm of gene therapy, the use of trans-splicing to modify the genetic repertoire at the pre-mRNA level to treat genetic and acquired disorders. Therapeutic trans-splicing can be used to alter coding domains, to create novel fusion proteins, to direct gene products to various cellular compartments, and to overcome some of the limitations to vector-derived gene transfer technology, including gene therapy with large genes or with genes coding for toxic proteins. To demonstrate the potential of therapeutic trans-splicing, eukaryotic cis-splicing and trans-splicing are reviewed, followed by a discussion of strategies of therapeutic pre-mRNA trans-splicing directed by exogenous gene transfer.

Original languageEnglish
Pages (from-to)695-709
Number of pages15
JournalComptes Rendus - Biologies
Volume327
Issue number8
DOIs
Publication statusPublished - 1 Aug 2004
Externally publishedYes

Fingerprint

Trans-Splicing
trans-splicing
RNA Precursors
genetic engineering
Medicine
medicine
Gene therapy
Genes
gene therapy
RNA
therapeutics
Gene transfer
Genetic Therapy
gene transfer
genes
Therapeutics
Poisons
Transcription
Technology Transfer
translation (genetics)

Keywords

  • Gene therapy
  • Trans-splicing

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Genetic medicine at the RNA level : Modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing. / Pergolizzi, Robert G.; Crystal, Ronald.

In: Comptes Rendus - Biologies, Vol. 327, No. 8, 01.08.2004, p. 695-709.

Research output: Contribution to journalReview article

@article{31b07eccfb6048a49487764068264428,
title = "Genetic medicine at the RNA level: Modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing",
abstract = "Gene therapy is conventionally carried out by transferring genetic material to the target cell where the exogenous gene is expressed using the endogenous transcription and translation machinery in parallel with the target cell genome. This review focuses on a new paradigm of gene therapy, the use of trans-splicing to modify the genetic repertoire at the pre-mRNA level to treat genetic and acquired disorders. Therapeutic trans-splicing can be used to alter coding domains, to create novel fusion proteins, to direct gene products to various cellular compartments, and to overcome some of the limitations to vector-derived gene transfer technology, including gene therapy with large genes or with genes coding for toxic proteins. To demonstrate the potential of therapeutic trans-splicing, eukaryotic cis-splicing and trans-splicing are reviewed, followed by a discussion of strategies of therapeutic pre-mRNA trans-splicing directed by exogenous gene transfer.",
keywords = "Gene therapy, Trans-splicing",
author = "Pergolizzi, {Robert G.} and Ronald Crystal",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.crvi.2004.05.008",
language = "English",
volume = "327",
pages = "695--709",
journal = "Comptes Rendus - Biologies",
issn = "1631-0691",
publisher = "Elsevier Masson",
number = "8",

}

TY - JOUR

T1 - Genetic medicine at the RNA level

T2 - Modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing

AU - Pergolizzi, Robert G.

AU - Crystal, Ronald

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Gene therapy is conventionally carried out by transferring genetic material to the target cell where the exogenous gene is expressed using the endogenous transcription and translation machinery in parallel with the target cell genome. This review focuses on a new paradigm of gene therapy, the use of trans-splicing to modify the genetic repertoire at the pre-mRNA level to treat genetic and acquired disorders. Therapeutic trans-splicing can be used to alter coding domains, to create novel fusion proteins, to direct gene products to various cellular compartments, and to overcome some of the limitations to vector-derived gene transfer technology, including gene therapy with large genes or with genes coding for toxic proteins. To demonstrate the potential of therapeutic trans-splicing, eukaryotic cis-splicing and trans-splicing are reviewed, followed by a discussion of strategies of therapeutic pre-mRNA trans-splicing directed by exogenous gene transfer.

AB - Gene therapy is conventionally carried out by transferring genetic material to the target cell where the exogenous gene is expressed using the endogenous transcription and translation machinery in parallel with the target cell genome. This review focuses on a new paradigm of gene therapy, the use of trans-splicing to modify the genetic repertoire at the pre-mRNA level to treat genetic and acquired disorders. Therapeutic trans-splicing can be used to alter coding domains, to create novel fusion proteins, to direct gene products to various cellular compartments, and to overcome some of the limitations to vector-derived gene transfer technology, including gene therapy with large genes or with genes coding for toxic proteins. To demonstrate the potential of therapeutic trans-splicing, eukaryotic cis-splicing and trans-splicing are reviewed, followed by a discussion of strategies of therapeutic pre-mRNA trans-splicing directed by exogenous gene transfer.

KW - Gene therapy

KW - Trans-splicing

UR - http://www.scopus.com/inward/record.url?scp=9244230654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244230654&partnerID=8YFLogxK

U2 - 10.1016/j.crvi.2004.05.008

DO - 10.1016/j.crvi.2004.05.008

M3 - Review article

C2 - 15506518

AN - SCOPUS:9244230654

VL - 327

SP - 695

EP - 709

JO - Comptes Rendus - Biologies

JF - Comptes Rendus - Biologies

SN - 1631-0691

IS - 8

ER -